Daito Pharmaceutical Co (TSE:4577) Change In Receivables: 円0 Mil (TTM As of May. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4577 Daito Pharmaceutical Co Ltd TSE:4577
80 GF Score
Price 円1,321.00
GF Value 円1,288.34
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Daito Pharmaceutical Co Change In Receivables?

Daito Pharmaceutical Co TSE:4577 -0.90% 80 Change In Receivables is 円0 Mil as of May. 2026. GuruFocus rates TSE:4577 with a GF Score™ of 80/100 and a GF Value™ of 円1,288.34 (Fairly Valued). The stock has 3 warning signs investors should review.

Daito Pharmaceutical Co's change in receivables for the quarter that ended in May. 2026 was 円0 Mil. It means Daito Pharmaceutical Co's Accounts Receivable stayed the same from Feb. 2026 to May. 2026 .

Daito Pharmaceutical Co's change in receivables for the fiscal year that ended in May. 2026 was 円1,355 Mil. It means Daito Pharmaceutical Co's Accounts Receivable declined by 円1,355 Mil from May. 2025 to May. 2026 .

Daito Pharmaceutical Co's Accounts Receivable for the quarter that ended in May. 2026 was 円12,792 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Daito Pharmaceutical Co's Days Sales Outstanding for the three months ended in May. 2026 was 83.87.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Daito Pharmaceutical Co's liquidation value for the three months ended in May. 2026 was 円-1,587 Mil.

Daito Pharmaceutical Co  (TSE:4577) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Daito Pharmaceutical Co's Days Sales Outstanding for the quarter that ended in May. 2026 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=12792/13918*91
=83.87

2. In Ben Graham's calculation of liquidation value, Daito Pharmaceutical Co's accounts receivable are only considered to be worth 75% of book value:

Daito Pharmaceutical Co's liquidation value for the quarter that ended in May. 2026 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=954-20354+0.75 * 12792+0.5 * 16439
=-1,587

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Daito Pharmaceutical Co Change In Receivables Related Terms

Daito Pharmaceutical Co Change In Receivables Historical Data

* Premium members only.

The historical data trend for Daito Pharmaceutical Co's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Daito Pharmaceutical Co Change In Receivables Chart

Daito Pharmaceutical Co Annual Data
Trend May17 May18 May19 May20 May21 May22 May23 May24 May25 May26
Change In Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3,299.00 -1,502.00 2,221.00 -3,702.00 1,355.00

Daito Pharmaceutical Co Quarterly Data
Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26 May26
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
TSE:4577
80GF Score
Daito Pharmaceutical Co Ltd TSE:4577
Change In Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Daito Pharmaceutical Co Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in May. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Receivables →
What does a Change In Receivables of 円0 Mil mean?
Daito Pharmaceutical Co (TSE:4577) has a Change In Receivables of 円0 Mil as of May. 2026. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Daito Pharmaceutical Co and its competitors.
Is Daito Pharmaceutical Co's Change In Receivables too high?
Daito Pharmaceutical Co's current Change In Receivables is 円0 Mil. Overall, Daito Pharmaceutical Co has a GF Score™ of 80/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Daito Pharmaceutical Co's Change In Receivables compare to ZTS?
Daito Pharmaceutical Co's Change In Receivables of 円0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Drug Manufacturers company?
A good Change In Receivables depends on the Drug Manufacturers industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Daito Pharmaceutical Co and its competitors. Daito Pharmaceutical Co's current Change In Receivables is 円0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Daito Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Daito Pharmaceutical Co (TSE:4577) is currently considered Fairly Valued. The stock's GF Value™ is 円1,288.34, compared to a current price of 円1,321.00 — trading 2.5% above its estimated fair value. The current Change In Receivables is 円0 Mil. Daito Pharmaceutical Co's overall GF Score™ is 80/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For Daito Pharmaceutical Co (TSE:4577), the current Change In Receivables is 円0 Mil as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Daito Pharmaceutical Co (TSE:4577) Overvalued in 2026?

Based on GuruFocus' analysis, Daito Pharmaceutical Co stock appears to be overvalued. The current stock price of 円1,321.00 is trading 2.5% above its estimated GF Value™ of 円1,288.34. GuruFocus considers Daito Pharmaceutical Co to be Fairly Valued.

Key valuation signals for TSE:4577:

  • Change In Receivables: 円0 Mil
  • GF Value™: 円1,288.34 vs. price of 円1,321.00 (2.5% above fair value)
  • GF Score™: 80/100 with 3 warning signs

No single metric tells the full story. See the TSE:4577 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Daito Pharmaceutical Co Business Description

Address 326 Yokamachi, Toyama, JPN, 939-8567
Daito Pharmaceutical Co Ltd is engaged in the research and development of pharmaceutical products. The company also undertakes contract manufacturing.
80GF Score

Get the complete analysis for TSE:4577

Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円1,321.00
Price
円1,288.34
GF Value